Rakuten Medical, a developer of cancer treatments partly owned by Japan’s Rakuten Group, completed a fundraising round as it ...

Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserve ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – ...

Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and ...

EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 ---- Phase 3 PREVAIL CVOT overall event rate ...

Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...

In July, the FDA issued a complete response letter (CRL) for Replimune's biologics license application for RP1 (vusolimogene ...

There is a significant unmet need for additional treatment options for high-grade NMIBC, especially in those ineligible for BCG.

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with ...

The devastating consequences of mucopolysaccharidosis II (MPS II), also called Hunter syndrome, may soon become preventable ...

Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting. Researchers determined the BrECADD combination ...